SG11201708151TA - Method of monomerisation of recombinant antibody molecules - Google Patents

Method of monomerisation of recombinant antibody molecules

Info

Publication number
SG11201708151TA
SG11201708151TA SG11201708151TA SG11201708151TA SG11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA SG 11201708151T A SG11201708151T A SG 11201708151TA
Authority
SG
Singapore
Prior art keywords
monomerisation
antibody molecules
recombinant antibody
recombinant
molecules
Prior art date
Application number
SG11201708151TA
Inventor
Sam Philip Heywood
Gavin Barry Wild
Razwan Hanif
Page Christopher John Le
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of SG11201708151TA publication Critical patent/SG11201708151TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123Tripeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201708151TA 2015-04-22 2016-04-22 Method of monomerisation of recombinant antibody molecules SG11201708151TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506870.3A GB201506870D0 (en) 2015-04-22 2015-04-22 Method
PCT/EP2016/059051 WO2016170138A1 (en) 2015-04-22 2016-04-22 Method of monomerisation of recombinant antibody molecules

Publications (1)

Publication Number Publication Date
SG11201708151TA true SG11201708151TA (en) 2017-11-29

Family

ID=53299019

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708151TA SG11201708151TA (en) 2015-04-22 2016-04-22 Method of monomerisation of recombinant antibody molecules

Country Status (17)

Country Link
US (2) US10828366B2 (en)
EP (1) EP3286204B1 (en)
JP (1) JP6898251B2 (en)
KR (1) KR20170138552A (en)
CN (1) CN108064230B (en)
AU (1) AU2016251620A1 (en)
BR (1) BR112017021812A2 (en)
CA (1) CA2981644C (en)
CL (1) CL2017002676A1 (en)
CO (1) CO2017010385A2 (en)
EA (1) EA201792329A1 (en)
ES (1) ES2846732T3 (en)
GB (1) GB201506870D0 (en)
IL (1) IL254765A0 (en)
MX (1) MX2017013376A (en)
SG (1) SG11201708151TA (en)
WO (1) WO2016170138A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
IL252712B2 (en) 2014-12-22 2024-04-01 UCB Biopharma SRL Method of protein manufacture
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
AU2019356564A1 (en) * 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2022122654A1 (en) * 2020-12-07 2022-06-16 UCB Biopharma SRL Multi-specific antibodies and antibody combinations

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (en) 1987-07-01 1987-07-01 Novo Industri As immobilization
US5453363A (en) 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
ATE269401T1 (en) 1991-04-10 2004-07-15 Scripps Research Inst LIBRARIES OF HETERODIMERIC RECEPTORS USING PHAGEMIDS
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
DE69233745D1 (en) 1991-12-02 2008-10-23 Cambridge Antibody Tech Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
EP0744958B1 (en) 1994-01-31 2003-06-25 Trustees Of Boston University Polyclonal antibody libraries
FR2716640B1 (en) 1994-02-28 1996-05-03 Procedes Machines Speciales Device for centering and blocking a workpiece with a view to running it in using an expansion lapper.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
JP4799736B2 (en) * 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ Antibody fragment targeted immunoliposomes for systemic gene delivery
WO2010036767A1 (en) * 2008-09-26 2010-04-01 Schering Corporation High titer antibody production
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2545745T3 (en) 2002-05-02 2015-09-15 Wyeth Holdings Llc Transporter conjugates derived from caliqueamycin
WO2003097669A2 (en) * 2002-05-17 2003-11-27 Københavns Universitet Method for purifying denatured proteins having a desired disulfide bond configuration
CA2507004A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1644412T2 (en) 2003-07-01 2018-11-30 Ucb Biopharma Sprl Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
MX2007004437A (en) 2004-10-22 2007-06-20 Amgen Inc Methods for refolding of recombinant antibodies.
AU2006272714A1 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Compositions and methods for protein deaggregation
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
SG2013061528A (en) 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
LT2334705T (en) 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biological products
MX2011013417A (en) 2009-06-25 2012-03-29 Amgen Inc Capture purification processes for proteins expressed in a non-mammalian system.
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
BR112012022518A2 (en) * 2010-03-17 2020-10-13 Biogenerix Gmbh method for obtaining biologically active recombinant human g-csf
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
EP2550297B1 (en) 2010-03-25 2019-01-23 UCB Biopharma SPRL Disulfide stabilized dvd-lg molecules
US9193760B2 (en) * 2010-09-20 2015-11-24 Bio-Rad Laboratories, Inc. Dissociation of product-complexed contaminants in chromatography
US8759617B2 (en) * 2010-09-21 2014-06-24 National Institute Of Agrobiological Sciences Method for extraction and purification of recombinant proteins from transgenic plants
CA2847888A1 (en) * 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
EA033766B1 (en) * 2011-11-11 2019-11-22 Ucb Biopharma Sprl Albumin binding antibodies and binding fragments thereof
UA112203C2 (en) 2011-11-11 2016-08-10 Юсб Фарма С.А. Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin
US20160060291A1 (en) 2012-03-30 2016-03-03 Biogenomics Limited Process for renaturation of polypeptides
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
DK3447069T3 (en) * 2012-11-21 2020-11-16 Janssen Biotech Inc BISPECIFIC EGFR / C-MET ANTIBODIES
EP3114223A1 (en) 2014-03-07 2017-01-11 Bionano Genomics, Inc. Processing of polynucleotides
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20190038896A (en) 2016-08-12 2019-04-09 론자 리미티드 Proteomic analysis of host cell proteins

Also Published As

Publication number Publication date
CN108064230B (en) 2021-04-06
ES2846732T3 (en) 2021-07-29
EP3286204B1 (en) 2020-11-18
JP6898251B2 (en) 2021-07-07
US11786593B2 (en) 2023-10-17
CA2981644A1 (en) 2016-10-27
US20180117153A1 (en) 2018-05-03
JP2018515449A (en) 2018-06-14
EA201792329A1 (en) 2018-02-28
IL254765A0 (en) 2017-12-31
WO2016170138A1 (en) 2016-10-27
US10828366B2 (en) 2020-11-10
CN108064230A (en) 2018-05-22
GB201506870D0 (en) 2015-06-03
CA2981644C (en) 2023-07-04
US20210069328A1 (en) 2021-03-11
MX2017013376A (en) 2017-12-07
CL2017002676A1 (en) 2018-03-23
BR112017021812A2 (en) 2018-07-10
KR20170138552A (en) 2017-12-15
EP3286204A1 (en) 2018-02-28
CO2017010385A2 (en) 2018-03-20
AU2016251620A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IL285366A (en) Multispecific antigen-binding proteins
ZA201907054B (en) Anti-tau antibodies and methods of use
HK1254198A1 (en) Optimized variants of anti-vegf antibodies
IL249955A0 (en) Method of computational protein design
GB201601075D0 (en) Antibodies molecules
IL254765A0 (en) Method of monomerisation of recombinant antibody molecules
GB201522391D0 (en) Antibody molecules
HK1251582A1 (en) Humanized anti-tau(ps422) antibodies and methods of use
IL248697A0 (en) Methods of purifying antibodies
GB201518792D0 (en) Production of proteins
IL255094A0 (en) Method for increasing the percentage of monomeric antibody fab-dsfv multimeric species
HUP1500363A2 (en) Method for increasing the galactose content of recombinant proteins
GB201604627D0 (en) Improved method of FT-IMS
LT3337820T (en) An improved refolding process for antibody`s fragments
IL258981A (en) Methods for producing proteins
SG11201800894SA (en) Method for parallel quantification of protein variant
HK1255456A1 (en) Expression of fc-containing proteins
IL252712A0 (en) Method of protein manufacture
IL248694A0 (en) Nanoencapsulation of antigen-binding molecules
GB201518675D0 (en) Detection of structural forms of proteins
HK1255728A1 (en) Treatment of asthma with anti-il-23a antibodies
IL256707B (en) Method for production of recombinant proteins
IL256706B (en) Method for production of recombinant proteins
GB201509048D0 (en) Method of assembly
IL251740B (en) A method of producing vials of recombinant protein